(Q40057379)

English

Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs

scientific article published on 17 October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

author name string

Srdjan Novaković

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Vida Stegel

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Andreja Kopitar

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Alojz Ihan

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Barbara Jezersek Novaković

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

language of work or name

0 references

publication date

17 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

8241-8256

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

A Toll-like receptor recognizes bacterial DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Recognition of single-stranded RNA viruses by Toll-like receptor 7

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Discrimination of bacterial lipoproteins by Toll-like receptor 6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Toll-like receptors, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Successful combination of local CpG-ODN and radiotherapy in malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Toll-like receptor control of the adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

In vivo manipulation of dendritic cells to induce therapeutic immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Clinical applications of dendritic cell vaccination in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Dendritic cells incubated with irradiated tumor cells effectively stimulate T lymphocyte activation and induce enhanced expression of CD69, CD25 as well as production of IFNgamma and IL4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Effector and memory T-cell differentiation: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Progressive differentiation and selection of the fittest in the immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

T-cell immunity in the induction and maintenance of a tumour dormant state

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.067

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.09.067

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40057379&oldid=1883388926"